The report published by the National Health Fund on the drug program in plasmocytic myeloma is one of the first such broad studies based on real-world data. As NFZ President Marek Augustyn stresses, the project should be seen as a "new opening" for cooperation between the public payer, the scientific community and clinicians, and the beginning of a wider use of data to improve the quality of treatment.
Patient Empowerment 2026
Marek Augustyn: NFZ report on myeloma is a "watershed moment"
Published May 20, 2026 07:50
The NFZ report on the drug program in plasmocytic myeloma may open a new stage in monitoring the quality of treatment in oncology and hematology, NFZ President Marek Augustyn assessed. - The end of March, that is, the moment when this very report came out, can be assessed as a watershed moment, he said.
As he added, the report is a "new opening" for cooperation between public entities, the scientific community and clinicians - It is a new opening to all elements of cooperation: public entities with scientific entities, clinics and professionals in the field, he noted.
The NFZ president also stressed the importance of using data collected in the health care system. - This shows the trend we should follow, which is to use the very specific data that is in our resources to improve therapeutic pathways, to improve quality for patients, he said. - And this is the main goal of this cooperation," he added.
